Neutralizing AVP monoclonal antibody (COR-ZZZ)

Corteria Pharmaceuticals develops a neutralizing vasopressin human monoclonal IgG1 that bears the potential to cure hyponatremic worsening heart failure. It is expected to normalize the natremia and improve the cardiac and renal functions through the simultaneous absence of systemic activation of V1a, V1b and V2 receptors. Proof of concept has been established in preclinical models.